EMC Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

EMC Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$152K	Sell	6,525 -1,152	-15%	-$25.7K	0.07%	108
2025 Q3	$151K	Hold	7,677	–	–	0.07%	134
2025 Q2	$167K	Sell	7,677 -7,084	-48%	-$167K	0.09%	107
2025 Q1	$358K	Hold	14,761	–	–	0.22%	65
2024 Q4	$308K	Buy	14,761 +12,340	+510%	+$265K	0.17%	92
2024 Q3	$103K	Sell	2,421 -12,340	-84%	-$229K	0.07%	227
2024 Q2	$229K	Hold	14,761	–	–	0.13%	131
2024 Q1	$235K	Sell	14,761 -13,722	-48%	-$207K	0.14%	142
2023 Q4	$479K	Hold	28,483	–	–	0.32%	33
2023 Q3	$333K	Hold	28,483	–	–	0.24%	58
2023 Q2	$383	Hold	28,483	–	–	0.3%	43
2023 Q1	$472K	Hold	28,483	–	–	0.4%	23
2022 Q4	$530K	Hold	28,483	–	–	0.48%	14
2022 Q3	$365K	Hold	28,483	–	–	0.34%	27
2022 Q2	$200K	Sell	28,483 -21,660	-43%	-$159K	0.17%	109
2022 Q1	$382K	Buy	+50,143	New	+$354K	0.27%	42

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EMC Capital Management's CPRX Position: Q4 2025 in Review

EMC Capital Management reduced its Catalyst Pharmaceutical (CPRX) stake by 15% in Q4 2025, selling an estimated $25.7K and leaving 6,525 shares worth $152K. The position accounts for 0.07% of the portfolio, ranked #108.

EMC Capital Management first reported a position in CPRX in Q1 2022 and has held it in 16 quarters since. The position peaked at $530K in Q4 2022. 373 funds tracked by Wall St. Rank hold CPRX as of Q4 2025.

EMC Capital Management held 6,525 shares of Catalyst Pharmaceutical worth $152K as of Q4 2025.
EMC Capital Management sold 1,152 Catalyst Pharmaceutical shares in Q4 2025, an estimated $25.7K.
Catalyst Pharmaceutical made up 0.07% of EMC Capital Management's portfolio in Q4 2025, its #108 holding.
EMC Capital Management first reported a position in Catalyst Pharmaceutical in Q1 2022 and has held it in 16 quarters since.
EMC Capital Management's Catalyst Pharmaceutical position peaked at $530K in Q4 2022.
373 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2025.

Based on EMC Capital Management's 13F filing for Q4 2025, filed 9 Mar 2026.